New delivery strategies for the old pentavalent antimonial drugs

被引:68
作者
Frezard, Frederic [1 ]
Demicheli, Cynthia [2 ]
机构
[1] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Fisiol & Biofis, BR-31270901 Belo Horizonte, MG, Brazil
[2] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Quim, BR-31270901 Belo Horizonte, MG, Brazil
关键词
antimony; cyclodextrin; dogs; immunochemotherapy; leishmaniasis; liposomes; meglumine antimoniate; microparticle; pentavalent antimonials; stibogluconate; LIPOSOMAL AMPHOTERICIN-B; EXPERIMENTAL VISCERAL LEISHMANIASIS; STEARYLAMINE-BEARING LIPOSOMES; MEGLUMINE ANTIMONIATE; SODIUM STIBOGLUCONATE; CUTANEOUS LEISHMANIASIS; BETA-CYCLODEXTRIN; BONE-MARROW; BALB/C MICE; RETICULOENDOTHELIAL SYSTEM;
D O I
10.1517/17425247.2010.529897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Pentavalent antimonials are the first-line drugs for treatment of the major tropical disease leishmaniasis. However, their use is limited by the need for daily parenteral administration, their severe side effects and treatment failures. As leishmaniasis belongs to the group of neglected diseases, the improvement of old drugs through new delivery approaches has more support than the development of new chemical entities. Areas covered in this review: The review covers, from 1977 to the present, the progress achieved towards pharmaceutically acceptable liposome-based formulations of antimonials, identification of specific ligands for improved targeting of infected macrophages and new approaches for oral and topical delivery of antimonial drugs. What the reader will gain: Insights into the most promising delivery strategies to improve antimonial therapy and the chemical basis and future directions for achieving innovative orally and topically effective formulations. Take home message: The development of drug delivery strategies for the old pentavalent antimonials is a still growing and promising field, with expected innovations in the near future from improved knowledge of antimony chemistry.
引用
收藏
页码:1343 / 1358
页数:16
相关论文
共 98 条
[21]  
BURGUERA JL, 1993, TRACE ELEM MED, V10, P66
[22]   THE THERAPEUTIC EFFECT OF SODIUM STIBOGLUCONATE IN BALB/C MICE INFECTED WITH LEISHMANIA-DONOVANI IS ORGAN-DEPENDENT [J].
CARTER, KC ;
BAILLIE, AJ ;
ALEXANDER, J ;
DOLAN, TF .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1988, 40 (05) :370-373
[23]   VISCERAL LEISHMANIASIS - DRUG CARRIER SYSTEM CHARACTERISTICS AND THE ABILITY TO CLEAR PARASITES FROM THE LIVER, SPLEEN AND BONE-MARROW IN LEISHMANIA-DONOVANI INFECTED BALB/C MICE [J].
CARTER, KC ;
DOLAN, TF ;
ALEXANDER, J ;
BAILLIE, AJ ;
MCCOLGAN, C .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1989, 41 (02) :87-91
[24]  
CHAPMAN WL, 1984, AM J VET RES, V45, P1028
[25]   PHARMACOKINETICS OF ANTIMONY DURING TREATMENT OF VISCERAL LEISHMANIASIS WITH SODIUM STIBOGLUCONATE OR MEGLUMINE ANTIMONIATE [J].
CHULAY, JD ;
FLECKENSTEIN, L ;
SMITH, DH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1988, 82 (01) :69-72
[26]  
Costa J M, 1986, Rev Soc Bras Med Trop, V19, P199
[27]  
Croft S. L., 1989, Leishmaniasis: The current status and new strategies for control. Proceedings of a NATO Advanced Study Institute on leishmaniasis: The first centenary (1885-1985), new strategies for control, Zakinthos, Greece, 20-27 September 1987., P783
[28]   TARGETING OF UREA STIBAMINE ENCAPSULATED IN LIPOSOMES TO RETICULOENDOTHELIAL SYSTEM FOR THE TREATMENT OF EXPERIMENTAL LEISHMANIASIS [J].
DAS, N ;
MAHATO, SB ;
NASKAR, K ;
GHOSH, DK ;
BASU, MK .
BIOCHEMICAL MEDICINE AND METABOLIC BIOLOGY, 1990, 43 (02) :133-139
[29]   Synthesis and characterization of Sb(V)-adenosine and Sb(V)-guanosine complexes in aqueous solution [J].
Demicheli, C ;
Santos, LS ;
Ferreira, CS ;
Bouchemal, N ;
Hantz, E ;
Eberlin, MN ;
Frézard, F .
INORGANICA CHIMICA ACTA, 2006, 359 (01) :159-167
[30]   Antimony(V) complex formation with adenine nuelcosides in aqueous solution [J].
Demicheli, C ;
Frézard, F ;
Lecouvey, M ;
Garnier-Suillerot, A .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2002, 1570 (03) :192-198